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Introduction
Peroxisomes are membrane-enclosed organelles involved in a variety 
of metabolic pathways including α- and β-oxidation of fatty acids and 
synthesis of bile acids, cholesterol, and plasmalogens (1). Mutations 
in genes encoding peroxisomal proteins are associated with two 
different groups of peroxisomal disorders: isolated enzyme deficiencies 
affecting specific metabolic pathways and peroxisome biogenesis 
disorders (PBDs) causing a defect in the assembly and maintenance of 
peroxisomes (2). PBDs, including Zellweger spectrum disorders and 
rhizomelic chondrodysplasia punctuate, are mainly caused by mutations 
in PEX proteins. These proteins, also known as peroxins, are encoded 
by 16 different PEX genes (3). The phenotypic presentation can range 
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PEX11β ([OMIM] 614920) mutation causes an extremely rare subgroup 
of peroxisomal biogenesis disorders, with only six cases reported to 
date. In this article, we reported a patient with episodic migraine-
like attacks, delirium, mood and behavior change, polyneuropathy, 
and history of congenital cataract. Whole exome sequencing showed 
novel c.743_744delTCinsA mutation in the exon 4 of the PEX11β 
gene. In contrast to previously reported patients, our case presented 
milder features and extended the spectrum of the clinical phenotype 
of this mutation. This study helps to extend the phenotype of this 
syndrome; besides, recognizing novel mutation variants will provide 
a better genotype-phenotype correlation and improve clinical clues.
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from mild to severe and early to late due to genetic 
heterogeneity (2).
PEX11 family members encode peroxisomal 
membrane proteins which coordinate peroxisome 
proliferation and maintenance and have a direct 
role in the metabolism of fatty acids (4, 5). Among 
PEX11 gene subgroups, recently, six patients have 
been reported to have PEX11β mutations ([OMIM] 
614920) with various clinical presentations. In this 
article, we reported a patient with a novel mutation 
in the PEX11β gene and new clinical features.
Case Report
A 15-year-old boy was referred to our hospital with 
presenting symptoms of nausea, vomiting, severe 
headache, delirium, and a complaint of mood 
and behavior change. He was the first child of 
consanguineous parents born at term with a birth 
weight of 3.1 kg. He had no history of intellectual 
disability, but a mild motor developmental delay 
was reported in his past medical history; he started 
walking at 18 months. He was diagnosed with 
bilateral cataracts at birth and underwent surgery 
in his 40 days of life, but no further workup was 
performed at that time. When he was 2.5 years old, 
he experienced three episodes of clonic seizure 
attacks during one month; however, EEG and MRI 
did not show abnormalities at that time. He did not 
experience any symptoms until 11 years of age 
when an episode of fever, confusion, and delirium 
occurred. CBC, blood biochemistry, lumbar 
puncture analysis, and brain MRI were all normal 
at that time, and a diagnoses of viral encephalitis 
was made. He experienced similar episodes at 
the age of 13. His parents stated that he exhibited 
behavioral and emotional problems like childish 
talk and mood instability during the attacks and 
turned normal after the episodes terminated. He 
also experienced headaches with migraine-like 
features during these episodes. The episodes 
resolved spontaneously within two weeks, and no 
specific trigger was noted.
Upon physical examination, he was disoriented 
to time and place. He exhibited delirious state 
and childish behaviors like engaging in baby talk 
and short attention spans. He had a mild dry skin, 
mostly visible on the extremities and his face. 
Moreover, he had an abnormal gait and neurologic 
examination detected normal muscle tone and 
strength but reduced symmetrical reflexes in lower 
extremities. No significant abnormalities were 
found in other examinations.
Initial blood tests of the patient were within 
normal limits, and his liver function tests, 
lipid profile, ammonia, and lactate showed no 
abnormality. Further, no pathologic results were 
found in primary metabolic screening for fatty 
acid oxidation disorders, organic acidemias, and 
amino acid disorders. Urine organic acids and 
homocysteine levels as well as plasma amino acids 
levels measured with high performance liquid 
chromatography were normal. Moreover, plasma 
levels of very-long-chain fatty acids (C26:0, 
C24:0/C22:0, and C26:0/C22:0) and pristanic and 
phytanic acids revealed no abnormalities. The 
auditory brainstem response test was performed, 
and no defects were reported. On the other hand, 
the nerve conduction velocity test revealed both 
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sensory and motor polyneuropathy bilaterally in 
lower extremities.
With suspicion to mitochondrial or peroxisomal 
disorders, the mitochondrial treatment protocol 
(Vit B1, Vit B2, CoQ10, Vit E, b6, and L-carnitine 
selenium) was administered for the patient. The 
attack resolved in days with no significant clinical 
damage. 
Whole exome sequencing was requested due to 
the patient’s clinical features. DNA extracted 
from his blood was used to perform targeted gene 
capture using a custom capture kit. The obtained 
sequences were aligned to human reference 
genome (GRCh37/hg19) using the BWA program 
(6, 7) and analyzed using the Picard and GATK-
Lite toolkit. The result indicated that the novel 
c.743_744delTCinsA mutation was located in the 
exon 4 of the PEX11B gene, leading to a frameshift 
and premature truncation of three amino acids 
downstream to the codon 248 (p.Leu248GInfsTer3). 
Sanger sequencing confirmed that the patient was 
homozygous for this variant. This novel variant 
was predicted to be damaging by Mutation Taster 
and considered as a pathogenic variant mutation of 
the disease.
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Discussion
PBDs are a group of genetic inborn errors of 
metabolism, in which defective biogenesis 
of peroxisomes leads to complex clinical and 
metabolic phenotypes. Peroxisome biogenesis is 
controlled by proteins that encompass processes 
involved in the control of peroxisome size and 
number, and other proteins intervene in the assembly 
of matrix and membrane proteins on peroxisomes 
(8). Proteins involved in these processes are 
peroxins encoded by PEX genes, and dysfunction 
in 14 identical peroxins are associated with human 
diseases. PEX11β which was first linked to human 
disease in 2012 plays a role in peroxisome division 
and membrane elongation (9-11).
In 2012, Ebberink et al. reported the first patient with 
a homozygous nonsense mutation in the PEX11β 
gene. The patient was a 26-year-old Dutchman 
of non-consanguineous parents, presenting with 
a history of congenital cataract, mild intellectual 
disability, bilateral progressive hearing loss, 
gastrointestinal problems, polyneuropathy, and 
recurrent migraine-like episodes (12). In 2016, 
Taylor et al. described five individuals with novel 
biallelic loss of function mutations in the PEX11β 
gene from three different families. They were 
presented with congenital cataract, intellectual 
disability, seizure, hearing loss, gastrointestinal 
complaints, behavioral problems, and dry skin. 
Moreover, skeletal involvements and short stature 
were observed in some cases (Table 1).
Episodic migraine-like attacks presented in our 
patient were similar to those in a case reported 
by Ebberink et al. (12). Although periodic mood 
change with childish behavior during attacks 
may be classified as a spectrum of behavioral 
disturbances observed in previous PEX11β 
mutations, it should be noted that the periodic 
and resolving aspects of this feature were unique 
in our case. Polyneuropathy, which was shown 
in the first reported case, was demonstrated 
with milder symptoms in our patient. Hearing 
loss, as well as abnormal mental development, 
gastrointestinal complaints, and skeletal disorders 
were not developed in our case. History of bilateral 
congenital cataract was present in all of the reported 
patients, suggesting PBDs to be considered among 
differential diagnoses for congenital cataract (13). 
Congenital cataract is inherited in both autosomal 
dominant and recessive fashions and affects 2.5 
to 3.5 per 10000 births. Determining the genetic 
cause of congenital cataract could have significant 
clinical relevance by guiding genetic counseling 
and implementing early treatment strategies (14).
For many hereditary genetic disorders, disease 
severity is determined by the type of mutation and its 
impact on protein function. The milder phenotype 
in this patient suggests that the type and location 
of mutation in the PEX11β gene may be associated 
with the severity and divergence of symptoms. The 
novel mutation described in this article has not been 
reported previously. The consanguinity of parents 
is compatible with autosomal recessive inheritance 
described for this syndrome (13). Our findings 
expanded the spectrum and severity of the clinical 
phenotype associated with PEX11β variants. We 
also showed that PBDs could exist despite normal 
biochemical measurements, highlighting genetic 
analysis as an appropriate means for diagnosis of 
PEX11β variants when there is a high suspicion for 
presence of a systemic metabolic disease.
Because of the rarity of this disease, no treatment 
protocol has been established yet. Administering 
L-carnitine and the Co-Q10 enzyme in the first 
reported patient showed an overall improvement 
in his condition, although he still experiences 
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migraine-like attacks (12). In our patient, a 
mitochondrial treatment protocol was initiated in 
the last attack; however, it was discontinued after 
the symptoms resolved.
In Conclusion
PEX11β mutation causes an extremely rare 
subgroup of peroxisomal biogenesis disorders, 
with only seven cases reported to date. The main 
feature of the disease is congenital cataract that 
was developed in all of the reported cases. Normal 
metabolic tests in our case drew attention to the 
utility of genetic analysis when presence of a 
systemic metabolic disorder is likely. Extending 
the phenotype of this syndrome in addition to 
recognizing novel mutation variants will provide a 
better genotype-phenotype correlation and enhance 
clinical diagnostic clues.
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